Bepridil hydrochloride
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317318

CAS#: 74764-40-2

Description: Bepridil Hydrochloride is the hydrochloride salt form of bepridil, a calcium antagonist and class IV anti-arrhythmic agent. Bepridil hydrochloride blocks calcium entry through membranous calcium channels of coronary and peripheral vascular smooth muscle, thereby dilating coronary arteries and peripheral arterioles. This drug is used to treat chronic stable and variant angina pectoris. Bepridil hydrochloride has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.


Price and Availability

Size
Price

5mg
USD 100
Size
Price

10mg
USD 140
Size
Price

25mg
USD 190

Bepridil hydrochloride purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 317318
Name: Bepridil hydrochloride
CAS#: 74764-40-2
Chemical Formula: C24H35ClN2O2
Exact Mass: 418.23871
Molecular Weight: 419.0
Elemental Analysis: C, 68.80; H, 8.42; Cl, 8.46; N, 6.69; O, 7.64


Synonym: Angopril, Bepadin, Bepridil HCl, Bepridil hydrochloride, Bepridil hydrochloride monohydrate, CERM 1978, Cordium, UNII-4W2P15D93M, Vascor

IUPAC/Chemical Name: 1-Pyrrolideneethanamine, beta-((2-methylpropoxy)methyl)-N-phenyl-N-(phenylmethyl)-, monohydrochloride, monohydrate

InChi Key: QEKLYDIUTSRLQG-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H32N2O.ClH.H2O/c1-20(2)18-27-19-22(24-14-9-15-25-24)17-26(23-12-7-4-8-13-23)16-21-10-5-3-6-11-21;;/h3-8,10-13,20,22H,9,14-19H2,1-2H3;1H;1H2

SMILES Code: CC(C)COCC(C1=NCCC1)CN(C2=CC=CC=C2)CC3=CC=CC=C3.[H]Cl.[H]O[H]


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Noda K, Gotoh Y, Tanioka S, Narayama Y, Kobayashi M, Iwai S, Katoh N, Tadano
K. The relationship between the plasma concentration of bepridil and its efficacy
in the treatment of atrial fibrillation in Japanese patients. Biol Pharm Bull.
2012;35(5):672-6. PubMed PMID: 22687400.

2: Kang J, Chen XL, Ji J, Lei Q, Rampe D. Ca²⁺ channel activators reveal
differential L-type Ca²⁺ channel pharmacology between native and stem
cell-derived cardiomyocytes. J Pharmacol Exp Ther. 2012 May;341(2):510-7. doi:
10.1124/jpet.112.192609. Epub 2012 Feb 21. PubMed PMID: 22353878.

3: Noda K, Narayama Y, Goto Y, Kobayashi M, Kuronuma H, Iwai S, Itoh K, Katoh N,
Tadano K. An LC method for quantifying bepridil in human plasma using 1-naphthol
as the internal standard. J Chromatogr Sci. 2011 Aug;49(7):519-23. PubMed PMID:
21801483.

4: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin
Pharmacol. 2010 Jul-Aug;32(6):437-61. doi: 10.1358/mf.2010.32.6.1538165. PubMed
PMID: 20852754.

5: Peak E, Chalmers IW, Hoffmann KF. Development and validation of a
quantitative, high-throughput, fluorescent-based bioassay to detect schistosoma
viability. PLoS Negl Trop Dis. 2010 Jul 27;4(7):e759. doi:
10.1371/journal.pntd.0000759. PubMed PMID: 20668553; PubMed Central PMCID:
PMC2910722.

6: Márián T, Szabó-Péli J, Németh E, Trón L, Friedlander E, Szabó A, Balkay L,
Veress G, Krasznai Z. Na+/Ca2+ exchanger inhibitors modify the accumulation of
tumor-diagnostic PET tracers in cancer cells. Eur J Pharm Sci. 2007
Jan;30(1):56-63. Epub 2006 Oct 20. PubMed PMID: 17125978.

7: Yasuda M, Nakazato Y, Sasaki A, Kawano Y, Nakazato K, Tokano T, Daida H.
Clinical evaluation of adverse effects during bepridil administration for atrial
fibrillation and flutter. Circ J. 2006 Jun;70(6):662-6. PubMed PMID: 16723784.

8: Krasznai Z, Krasznai ZT, Morisawa M, Bazsáné ZK, Hernádi Z, Fazekas Z, Trón L,
Goda K, Márián T. Role of the Na+/Ca2+ exchanger in calcium homeostasis and human
sperm motility regulation. Cell Motil Cytoskeleton. 2006 Feb;63(2):66-76. PubMed
PMID: 16374831.

9: Saija A, Tomaino A, Pellegrino ML, Giuffrida N, Trombetta D, Castelli F. In
vitro evaluation of the antioxidant activity and biomembrane interaction of the
lazaroid U-74389G. Life Sci. 2001 Feb 9;68(12):1351-66. PubMed PMID: 11388688.

10: Brude IR, Drevon CA, Viken K, Arnstad JE, Valnes KN, Nenseter MS. Doxazosin
treatment and peroxidation of low-density lipoprotein among male hypertensive
subjects: in vitro and ex vivo studies. Biochem Pharmacol. 1999 Jul
1;58(1):183-91. PubMed PMID: 10403533.

11: Guo Q, Zhao B, Shen S, Hou J, Hu J, Xin W. ESR study on the
structure-antioxidant activity relationship of tea catechins and their epimers.
Biochim Biophys Acta. 1999 Mar 14;1427(1):13-23. PubMed PMID: 10082983.

12: Nenseter MS, Halvorsen B, Rosvold O, Rustan AC, Drevon CA. Paracetamol
inhibits copper ion-induced, azo compound-initiated, and mononuclear
cell-mediated oxidative modification of LDL. Arterioscler Thromb Vasc Biol. 1995
Sep;15(9):1338-44. PubMed PMID: 7670947.

13: Awni WM, Halstenson CE, Nayak RK, Opsahl JA, Desiraju RK, Minn FL, Matzke GR.
Pharmacokinetics of bepridil and two of its metabolites in patients with
end-stage renal disease. J Clin Pharmacol. 1995 Apr;35(4):379-83. PubMed PMID:
7650227.

14: Pritchard JF, Matzke GR, Opsahl JA, Halstenson CE, Nayak RK. Effects of
hemodialysis on plasma protein binding of bepridil. J Clin Pharmacol. 1995
Feb;35(2):137-41. PubMed PMID: 7751422.

15: Dinis TC, Maderia VM, Almeida LM. Action of phenolic derivatives
(acetaminophen, salicylate, and 5-aminosalicylate) as inhibitors of membrane
lipid peroxidation and as peroxyl radical scavengers. Arch Biochem Biophys. 1994
Nov 15;315(1):161-9. PubMed PMID: 7979394.

16: Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a
risk factor for torsades de pointes associated with cardiovascular drugs. JAMA.
1993 Dec 1;270(21):2590-7. PubMed PMID: 8230644.

17: Zusman RM, Higgins J, Christensen D, Boucher CA. Bepridil improves left
ventricular performance in patients with angina pectoris. J Cardiovasc Pharmacol.
1993 Sep;22(3):474-80. PubMed PMID: 7504141.

18: Katsumata K, Katsumata K Jr, Katsumata Y. Protective effect of diltiazem
hydrochloride on the occurrence of alloxan- or streptozotocin-induced diabetes in
rats. Horm Metab Res. 1992 Nov;24(11):508-10. PubMed PMID: 1452115.

19: Frishman WH. Comparative efficacy and concomitant use of bepridil and beta
blockers in the management of angina pectoris. Am J Cardiol. 1992 Apr
9;69(11):50D-55D. PubMed PMID: 1553892.

20: Shapiro W. Comparative efficacy of bepridil versus placebo in angina
pectoris: treatment and withdrawal studies. Am J Cardiol. 1992 Apr
9;69(11):43D-49D. PubMed PMID: 1553891.